Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114244 | 0.86 | HTR2C (0.57) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL14209521 | 0.86 | HTR2C (0.57) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL16925464 | 0.86 | HTR2C (0.51) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL5765666 | 0.84 | SMN1; SMN2 (0.49) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5765672 | 0.84 | SMN1; SMN2 (0.49) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18970283 | 0.84 | NPSR1 (0.56) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL1690517 | 0.84 | NPSR1 (0.56) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL12281877 | 0.84 | HTR2C (0.46) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL14420342 | 0.83 | PSEN1 (0.45) | HTR2CPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL202453 | 0.82 | NPSR1 (0.48) | HTR2CSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTR2C 4557/4885PDK1 3150/4885PDK2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.